 Opigolix

Opigolix (, ; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.It was also under investigation for the treatment of prostate cancer.